SSTR2 and neoplasm: This reduction was also reported in the study by Bernarjee [61], after 15 days of application, the PTX-loaded solid lipid nanoparticles (SLN) modified with Tyr-3-octreotide (TOC) (PSM) demonstrated great potential as a dual target for tumor neovasculature and tumor cells due to TOC (in PSM surface) interaction with SSTR2 expressed in endothelial cells of the neovasculature-improving the PTX antiangiogenic effects.